A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands by Gupta, A et al.
A four-kallikrein panel for the prediction of repeat prostate biopsy:
data from the European Randomized Study of Prostate Cancer
Screening in Rotterdam, Netherlands
A Gupta
1, MJ Roobol
2, CJ Savage
1, M Peltola
3, K Pettersson
2, PT Scardino
1, AJ Vickers
1, FH Schro ¨der
2
and H Lilja*,1,4
1Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA;
2Erasmus Medical Centre, Department of Urology, room
NH-224, P.O. Box 2040, 3000 CA, Rotterdam, Netherlands;
3Department of Biotechnology, University of Turku, Tykisto ¨katu 6 A 6th floor, FIN-20520
Turku, Finland;
4Lund University, Malmo ¨ University Hospital, Malmo ¨, Sweden
BACKGROUND: Most men with elevated levels of prostate-specific antigen (PSA) do not have prostate cancer, leading to a large
number of unnecessary biopsies. A statistical model based on a panel of four kallikreins has been shown to predict the outcome of a
first prostate biopsy. In this study, we apply the model to an independent data set of men with previous negative biopsy but
persistently elevated PSA.
METHODS: The study cohort consisted of 925 men with a previous negative prostate biopsy and elevated PSA (X3ngml
 1), with 110
prostate cancers detected (12%). A previously published statistical model was applied, with recalibration to reflect the lower positive
biopsy rates on rebiopsy.
RESULTS: The full-kallikrein panel had higher discriminative accuracy than PSA and DRE alone, with area under the curve (AUC)
improving from 0.58 (95% confidence interval (CI): 0.52, 0.64) to 0.68 (95% CI: 0.62, 0.74), Po0.001, and high-grade cancer (Gleason
X7) at biopsy with AUC improving from 0.76 (95% CI: 0.64, 0.89) to 0.87 (95% CI: 0.81, 0.94), P¼0.003). Application of the panel
to 1000 men with persistently elevated PSA after initial negative biopsy, at a 15% risk threshold would reduce the number of biopsies
by 712; would miss (or delay) the diagnosis of 53 cancers, of which only 3 would be Gleason 7 and the rest Gleason 6 or less.
CONCLUSIONS: Our data constitute an external validation of a previously published model. The four-kallikrein panel predicts the result
of repeat prostate biopsy in men with elevated PSA while dramatically decreasing unnecessary biopsies.
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Levels of prostate-specific antigen (PSA) in the blood are very
strongly associated with clinically significant prostate cancer,
whether in terms of high grade at diagnosis (Thompson et al, 2006)
or subsequent clinical diagnosis of advanced cancer (Ulmert et al,
2008). However, the PSA test has only modest diagnostic
specificity and positive predictive value for prostate cancer
detection at commonly used cut-points. This leads to significant
numbers of unnecessary biopsies. In the European Randomized
Study of Prostate Cancer screening (ERSPC), for example, the
positive biopsy rate among men with elevated PSA was 24.1%
(Schroder et al, 2009a), suggesting that three out of every four
biopsies were unnecessary. Similar findings have been reported
from US studies, such as the Prostate Cancer Prevention Trial
(PCPT) (Thompson et al, 2005). There is thus an urgent need to
supplement PSA with novel biomarkers that enhance its specificity
so that unnecessary biopsies can be avoided.
We have previously published a statistical model to predict the
results of prostate biopsy. The model includes age, DRE and a
panel of four kallikrein markers – total PSA, free PSA, intact PSA
and human kallikrein-related peptidase-2 (hK2). Using data from
the randomised prostate cancer screening trial in Go ¨teborg,
Sweden (one centre of the ERSPC), we estimated that for every
1000 previously unscreened men with elevated PSA, use of the
model to determine biopsy would reduce biopsy rates by 573, while
missing only a small number of cancers (31 out of 152 low-grade
cancers and 3 out of 40 high-grade cancers) (Vickers et al, 2008).
These findings were subsequently replicated in an independent
cohort (reduction in biopsy by 513 per 1000 men with elevated
PSA, missing 54 out of 177 low-grade cancer and 12 out of 100
high-grade cancers) (Vickers et al, 2010c). These findings have also
been replicated in men who recently have undergone previous
screening, with resultant improvements in predictive accuracy
(Vickers et al, 2010a,b).
The performance characteristics of PSA are known to be
influenced by previous screening, with predictive accuracy lower
in men who have previously been screened compared with an
unscreened cohort of men (Vickers et al, 2010a). Similarly, the
predictive accuracy of PSA to predict the outcome of repeat biopsy
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safter initial negative biopsy is also lower (Roobol et al, 2006; Walz
et al, 2006; Chun et al, 2007). In this study, we have evaluated the
performance characteristics of PSA in men who underwent a
second biopsy after an initial negative biopsy in the Rotterdam
section of the ERSPC. We then evaluated the performance
characteristics of the kallikrein panel in this cohort to see whether
it also could provide a more accurate prediction of repeat biopsy
outcome than currently established standard predictors. This also
serves as an independent validation of our previously published
model to predict the results of prostate biopsy.
MATERIALS AND METHODS
Patient methods
The study cohort comprised of participants in the Rotterdam
section of the ERSPC. The study design has been described
previously (Roobol et al, 2003). In brief, men aged 55–75 years
were invited for an initial PSA test during 1993–1999; men not
diagnosed with prostate cancer were invited for up to two
subsequent screens every 4 years until they reached age 75 years.
All biopsies were prompted by an elevated PSA (X3ngml
 1). A
total of 3394 patients had initial negative biopsy in rounds 1
through 3. Of these, 1000 men underwent a second biopsy in
subsequent rounds and 2394 men did not undergo a second biopsy
for various reasons (Figure 1). Biomarkers data were not available
for 75 of the 1000 men who underwent a second biopsy. Our
analysis is focused on the 925 men who underwent a second
prostate biopsy after an initial negative biopsy using an aliquot of
the blood collected before the second biopsy.
Laboratory methods
Laboratory methods were as for our previous publication (Vickers
et al, 2008). Serum samples were retrieved from the archival serum
bank in Rotterdam (where they had been stored frozen at  80
oC
after their initial processing within 3h from venipuncture) and
shipped frozen on dry ice to Malmo ¨, Sweden, in 2005–2007.
Analyses of free, total, and intact PSA and hK2 were performed in
Dr Lilja’s laboratory at the Wallenberg Research Laboratories,
Department of Laboratory Medicine, Lund University, University
Hospital UMAS in Malmo ¨, Sweden, during 2005 and 2007. Free and
total PSA were measured using the dual-label DELFIA Prostatus
total/free PSA-Assay (Perkin-Elmer, Turku, Finland) and con-
ducted in accordance with WHO calibration standards. The
measurements of intact PSA and hK2 entailed the use of F(ab0)2
fragments of the monoclonal capture antibodies in order to
significantly reduce the frequency of nonspecific assay interference
(Vaisanen et al, 2006). The intact PSA assay measures only free,
uncomplexed intact PSA (i.e., not cleaved at Lys145–Lys146). All
analyses were conducted blind to biopsy result.
Statistical methods
Our aim was to compare the area under the curve (AUC) of our
previously developed statistical model, which included age, DRE
result and a panel of four kallikrein markers vs that of a base
model that included age, DRE result and total PSA. To determine
the predictive value of our previously developed statistical model
(age, DRE and four kallikreins) above that of age, DRE and total
PSA alone, we looked at the area under the receiver operating
characteristic curve (AUC). High-grade cancer was defined as
biopsy Gleason score 7 or higher. Separate models were not built
for high-grade cancer, and the AUC for high-grade cancer was
calculated from the predicted probabilities of any cancer. The
predicted risk from the model was recalibrated with a Bayes factor,
using the observed event rate in this cohort (12%) to reflect the
lower incidence of cancer in men with previous negative biopsy.
Previous studies have reported higher rates of prostate cancer on
repeat biopsy, ranging from 11 to 34% (Keetch et al, 1994;
Roehrborn et al, 1996; Catalona et al, 1997; Fleshner et al, 1997;
Letran et al, 1998; Rietbergen et al, 1998; Durkan and Greene, 1999;
Djavan et al, 2000; O’Dowd et al, 2000; Stewart et al, 2001; Lopez-
Corona et al, 2003; Park et al, 2003; Lujan et al, 2004; Walz et al,
2006; Benecchi et al, 2008; Lane et al, 2008; Rochester et al, 2009;
Schroder et al, 2009b). Therefore, to examine the impact this
adjustment would have on calibration (discrimination would not
be affected) in cohorts with a different rate of cancer detection
2914 men biopsied in round 1
807 men with cancer in round 1
2107 men with first negative biopsy in round 1
1270 men not re-biopsied in round 2:
PSA <3.0: 181
Refused biopsy: 88
Died: 63
Age > 74 years: 415
Interval prostate cancer: 19
Seeing a urologist: 106
Refused participation for next round: 330
Unknown: 68
95 cancer 742 no cancer
871 men not re-biopsied in round 3:
PSA < 3.0: 184
Refused biopsy: 35
Died: 51
Age > 74 years: 278
Interval prostate cancer: 6
Seeing a urologist: 49
Refused participation for next round: 133
Unknown: 135
140 no cancer
163 men biopsied in round 3 after
negative biopsy in round 2*
1034 men first negative
biopsy in round 2
* Men with missing biomarker data
were excluded (n=57 and 18 from
round 2 and 3, respectively)
837 men biopsied in round 2 after negative
biopsy in round 1*
(all with PSA3 ng ml–1)
23 cancer
Figure 1 Flow chart of participants in the study.
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son repeat biopsy, we simulated higher event rates by randomly
sampling with replacement to create data sets with observed event
rates of 20 or 30%.
To illustrate the clinical effects of using the four-kallikrein
model in men with repeat biopsy, we used decision curve analysis.
Decision curve analysis estimates a ‘net benefit’ for prediction
models by summing the benefits (true positives) and subtracting
the harms (false positives), where the latter is weighted by a factor
so as to reflect the relative harm of a missed cancer compared with
an unnecessary biopsy. The weighting is derived from the
threshold probability of prostate cancer, defined as the point at
which a patient would choose to be biopsied. As this threshold
probability can vary from patient to patient, net benefit is
calculated across a range of probabilities; we chose 10–40% as a
reasonable range. The interpretation of a decision curve is
straightforward: the model with the highest net benefit at a
particular threshold probability should be used. All statistical
analyses were conducted using Stata 10.1 (StataCorp LP, College
Station, TX, USA).
RESULTS
Characteristics of the participants who were biopsied after a
previous negative biopsy are given in Table 1. In total, 110 (12%)
of 925 men had a positive biopsy after a previous negative biopsy.
The total PSA levels and age were only slightly higher for the men
with positive second biopsies compared with those with negative
biopsies (median total PSA: 5.61 vs 5.22ngml
 1 and age: 65 vs 64
years). As is typical for recently screened men, the majority of
cancers diagnosed were Gleason 6 or less (n¼92; 84%), whereas 13
(12%) were Gleason 7 and only 5 (5%) were Gleason 8 or higher.
The AUC of our previously developed model and base model
when applied to men with a previous negative biopsy are given in
Table 2. The AUC of the four-kallikrein panel was significantly
higher than the base model for the prediction of any prostate
cancer (AUC 0.681 (95% confidence interval (CI): 0.623, 0.739) vs
0.584 (95% CI: 0.523, 0.644), Po0.001) and high-grade cancer at
biopsy (AUC 0.873 (95% CI: 0.807, 0.939) vs 0.764 (95% CI: 0.639,
0.888), P¼0.003).
To put these results in a clinical context, we considered the
scenario where a clinician would recommend biopsy to men with a
predicted probability of 20% (Table 3). Applying this rule with the
kallikrein model would reduce the number of biopsies by 82%,
while delaying the diagnosis of 64 low-grade (Gleason sum p6a t
biopsy) and 3 high-grade cancers per 1000 men with persistently
elevated total PSA (X3ngml
 1). In other words, for every 272 men
who avoid biopsy, we miss only one high-grade cancer. In
addition, all the three high-grade cancers that were missed were
Gleason 7 and none of the cancers with Gleason score X8 were
missed. The very large reduction in biopsies conducted and
cancers found is due to the low event rate in this cohort. It seems
reasonable to assume that men with a previous biopsy might be
more risk averse than the population as a whole. Hence, we
repeated this analysis using a 15 and 10% risks as thresholds for
biopsy. Even at these lower risk thresholds, use of the model would
avoid 71 and 54% of the biopsies, whereas missing only 3 and 1
high-grade cancers, all of which were Gleason 7 (Table 3).
Figure 2 shows the decision curve for our full kallikrein model.
The net benefit of the four-kallikrein panel is superior to the
alternative strategies of either biopsying all men, no men or
biopsying on the basis of age, total PSA and DRE alone for all men,
except those requiring a very high (430%) risk of cancer before
accepting biopsy. Such men should not be biopsied after negative
biopsy, as their risk of subsequent positive biopsy is low.
As the event rate in this data set is lower than that previously
reported in men undergoing a repeat biopsy, we conducted a
sensitivity analysis to determine the effect of applying our
recalibrated model to a cohort of men, in which the true event
rate was higher (20 or 30%) than the event rate used for
recalibration (12%). When the true event rate was 20%, the
kallikrein model was superior to alternative treatment strategies
for all threshold probabilities above 12% (Figure 3A). However, at
an event rate of 30%, the kallikrein model was superior to a
strategy of biopsying all men only at threshold probabilities above
26% (Figure 3B). This may be because the model was calibrated to
a lower event rate of 12% and would likely need to be recalibrated
for use in cohorts, in which positive rebiopsy rates are 30%
or higher.
Several investigators have included prostate volume in pre-
dictive models for prostate cancer, for example, by calculating
‘PSA density’ (Radwan et al, 2007; Kranse et al, 2008). We have
previously avoided this approach on the grounds that data on
volume are only available when a transrectal ultrasound (TRUS)
probe is inserted during a prostate biopsy session. In the case of
repeat biopsy, however, TRUS-based prostate gland volume is
Table 1 Participant characteristics
No cancer
(N¼815)
Cancer
(N¼110)
Age at biopsy (years) 64 (61, 67) 65 (61, 68)
Total PSA (ngml
 1) 5.22 (4.07, 7.26) 5.61 (4.27, 8.93)
Free PSA (ngml
 1) 1.27 (0.93, 1.77) 1.22 (0.99, 1.61)
Intact PSA (ngml
 1) 0.67 (0.50, 0.96) 0.77 (0.52, 0.99)
Nicked PSA (ngml
 1) 0.58 (0.39, 0.87) 0.47 (0.31, 0.74)
hK2 (ngml
 1) 0.083 (0.058, 0.125) 0.101 (0.065, 0.141)
Abnormal DRE 173 (21%) 37 (34%)
Biopsy Gleason score
p6 — 92 (84%)
¼7 — 13 (12%)
X8 — 5 (5%)
Prostate volume at first biopsy
a 48.6 (39.5, 60.7) 43.8 (33.5, 53.2)
Abbreviations: DRE¼digital rectal examination; hK2¼human kallikrein-related
peptidase-2; PSA¼prostate-specific antigen. All values are median (interquartile
range) or frequency (proportion).
aMissing for four patients.
Table 2 Area under the curve of models built on first round Rotterdam
participants when applied participants in subsequent rounds with a previous
negative biopsy and elevated PSA (3ngml
 1 or higher)
Biopsy outcome
of any prostate
cancer
Biopsy outcome
of high-grade
prostate cancer
Main analysis
Base model (age, total
PSA and DRE)
0.584 (0.523, 0.644) 0.764 (0.639, 0.888)
Full model (age, kallikrein
panel, DRE)
0.681 (0.623, 0.739) 0.873 (0.807, 0.939)
P-value for difference between
base and full models
o0.001 0.003
Sensitivity analysis: including prostate volume at first biopsy
Base model (age, total PSA,
volume and DRE)
0.625 (0.567, 0.684) 0.839 (0.744, 0.933)
Full model (age, kallikrein
panel, volume, DRE)
0.677 (0.619, 0.736) 0.867 (0.800, 0.935)
P-value for difference between
base and full models
0.021 0.2
Abbreviations: DRE¼digital rectal examination; hK2¼human kallikrein-related
peptidase-2; PSA¼prostate-specific antigen. High-grade cancer is defined as Gleason
score X7. Full model includes age, total PSA (with splines), free PSA (with splines),
intact PSA, hK2 and DRE result.
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salready available from the original negative biopsy session. As a
sensitivity analysis, we added prostate volume to the base and full
models that were built on the first round of Rotterdam participants
and independently evaluated on men with a previous negative
biopsy. As shown in Table 2, TRUS-based prostate gland volume
increased the AUC of the base model, but not the full kallikrein
model, and AUC remained higher for the full model than for base
model (total PSA, age, and DRE) plus TRUS volume. The decision
curve was not substantively affected (data not shown). Our
conclusion that the kallikrein panel adds information to estab-
lished predictors is therefore unchanged.
DISCUSSION
In this study, we found that a panel of four kallikreins can predict
the outcome of prostate biopsy in men who had previously
undergone prostate biopsy during previous screening. The full
model comprised of the four kallikrein markers (i.e., total, free and
intact PSA, and hK2), age and DRE substantially improved the
predictive accuracy of a base model (comprising of total PSA, age
and DRE), for both low- and high-grade cancers.
We have previously reported similar improvements in AUC by
using the four-kallikrein panel in previously unscreened men and
in men who had undergone previous screening but had not been
biopsied; and have validated these findings in independent cohorts
(Vickers et al, 2008, 2010a,b,c). Among men who have not been
previously screened, use of the four-kallikrein panel increased the
AUC for detecting prostate cancer from 0.685 to 0.776 (Vickers
et al, 2010c). For men who have previously been screened but not
biopsied, the model increased AUC from 0.585 to 0.711 (Vickers
et al, 2010b).
These results also support our previous finding that the
predictive accuracy of PSA decreases in men who have previously
been screened. The AUC of a base model comprising of total PSA,
age and DRE was 0.584 to predict any cancer in this cohort as
compared with 0.724 for a cohort of men who had never been
screened (Vickers et al, 2008). The AUC of 0.584 in this study is
similar to the AUC of 0.569 and 0.585 in two cohorts of men who
had recently been screened in the ERSPC trial and undergone
initial prostate biopsy due to elevated PSA, but had no previous
biopsy (Vickers et al, 2010a,b). Similarly, for men with previous
negative biopsies, two large studies using clinical cohorts of men
Table 3 Clinical outcome of basing repeat biopsy on the kallikrein model
No. of biopsies No. of cancers No. of high-grade cancers
Performed Avoided (%) Found Not found (%) Found Not found (%)
Biopsy all (i.e., PSA43) 1000 0 (0) 119 0 (0) 19 0 (0)
Biopsy if risk X20% from the kallikrein model 183 817 (82) 52 67 (56) 16 3 (16)
a
Biopsy if risk X15% from the kallikrein model 288 712 (71) 66 53 (45) 16 3 (16)
a
Biopsy if risk X10% from the kallikrein model 459 541 (54) 82 37 (31) 18 1 (5)
a
Abbreviation: PSA¼prostate-specific antigen. Numbers are given per 1000 men with elevated PSA (X3ngml
 1).
aAll the high-grade cancers that were missed were Gleason 7.
None of the cancers with Gleason score X8 were missed.
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Figure 2 Decision curve for outcome of any cancer using the four-
kallikrein model (dashed line) and base model (solid line), after
recalibration. The solid grey line is for the strategy of biopsying all men
and the horizontal black line for not biopsying anyone. The line with the
highest net benefit at a particular threshold probability will lead to the best
clinical results.
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Figure 3 Decision curves for outcome of any cancer using the four-
kallikrein model (dashed line), compared with a strategy of biopsying all
men (solid grey line) or biopsying no men (solid black line) in cohorts in
which the event rate was imputed to be 20% (A) or 30% (B).
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shave found the AUC of total PSA alone to be modest at 0.528 and
0.601, respectively (Walz et al, 2006; Chun et al, 2007).
Men with prostate cancer after previous negative biopsy tend to
have favourable disease and their outcomes are better than those
diagnosed at the first screen (Schroder et al, 2009b). Most of these
cancers are low risk and are likely to constitute overdiagnosis.
Schroder et al (2009b) studied 3056 men in the Rotterdam arm of
the ERSPC who had initial negative biopsies at the first screen. On
follow-up up to 11 years, 287 prostate cancer cases were detected,
26 developed progressive disease and 7 died of prostate cancer
(Schroder et al, 2009b). Of these seven deaths only one was
diagnosed on repeat screening and the other six were interval
cancers. Only 0.6% of the prostate cancers diagnosed on repeat
screening after initial negative biopsy led to death, as compared
with 4.2% death rate for cancers found at initial biopsy. Thus, very
few cancers found after initial negative biopsy are clinically
relevant. Biopsying all men with previous negative biopsies will
lead to a large number of unnecessary biopsies and detection of a
large number of potentially clinically insignificant cancers. Hence,
a strategy of identifying and biopsying men at the greatest risk of
death due to cancer is needed.
In this cohort, of the 110 cancers that were diagnosed, 84% had
Gleason sum 6 or less on biopsy and only 5% were Gleason 8 or
more. Similarly in a series of 99 men enrolled in a large screening
programme with previous negative biopsies, 20 cancers were
found. Of these only one was clinically advanced, only 1 had
biopsy Gleason score 7 and three had Gleason score 7 on radical
prostatectomy. No patient had Gleason 8 or higher (Catalona et al,
1997). Hence, due to the relatively large number of clinically
insignificant cancers that exist in men with previous negative
biopsies, the goal in these men is to reduce the number of biopsies,
reduce the detection of clinically insignificant or indolent disease,
while still detecting the clinically significant cancers.
Use of the four-kallikrein model to predict the result of repeat
biopsy would lead to a very large reduction in the rate of
unnecessary second biopsy. Of the men with cancer who would be
classified at low risk from a model, the majority would have the
sort of low-stage, low-grade cancers typically thought to constitute
overdiagnosis. For example, if biopsy was based on patients having
a risk of cancer of 20% or more, use of the model would reduce the
number of biopsies by 82%. Of the 67 cancers that would
be missed, 64 would be Gleason 6 or less. The diagnosis will be
delayed for only 16% (3 of 19) of the high-grade cancers (Gleason
score¼7). For men who are more risk averse and would prefer to
undergo a biopsy at a 15% risk threshold, use of the model would
still reduce the biopsies by 712 per 1000 men, while missing 53
cancers only 3 of which would be Gleason 7. Thus, use of such
models may decrease the overdiagnosis and overtreatment
associated with repeated screening and repeat biopsy in men with
previous negative biopsies.
For men with previous negative biopsies and elevated PSA, use
of other markers such as PCA3 has been suggested. In men with
previous negative biopsies and persistently elevated PSA, a higher
PCA3 score has been found to be associated with a higher
probability of a positive biopsy (Marks et al, 2007; Haese et al,
2008). In a study of 463 men, use of a PCA3 score threshold of 20
would reduce 44% of the biopsies, while missing 9% of high-grade
cancers (Haese et al, 2008). A higher threshold, such as 35, would
avoid more biopsies (67%), but would also miss more high-grade
cancers (21%). Direct comparison of these results with ours is not
possible because ours is a screening cohort, whereas the PCA3
studies were based on clinical cohorts. The PCA3 test while
promising needs to be validated in independent cohorts, and the
PCA3 score needs to be incorporated into a model with other
predictors of a positive biopsy such as age, DRE, PSA and other
kallikreins. The need for an attentive DRE and collection of a urine
sample for PCA3 measurement may also limit its utility in a
screening scenario.
Several nomograms have also been developed to predict outcomes
of biopsy in men after previous negative biopsies (Shariat et al, 2008).
However, only a few of these have been externally validated (Lopez-
Corona et al, 2003; Yanke et al, 2005; Chun et al, 2007). These
nomograms have incorporated variables such as family history, PSA,
free PSA, PSA kinetics, PSA density, biopsy findings, number of
previous negative cores and so on. These nomograms were developed
in clinical cohorts and need to be studied in screening cohorts before
they can be used in a screening scenario.
Our study may be limited by the use of sextant biopsy, which
misses 19–23% of the cancers compared with the currently
practiced extended biopsy schemes (Schroder et al, 2009b). This
may partially explain why the cancer detection rate on rebiopsy
was 12% in this cohort compared with 11–19% reported in other
screening cohorts and 16–34% reported in clinical cohorts (Keetch
et al, 1994; Roehrborn et al, 1996; Catalona et al, 1997; Fleshner
et al, 1997; Letran et al, 1998; Rietbergen et al, 1998; Durkan and
Greene, 1999; Djavan et al, 2000; O’Dowd et al, 2000; Stewart et al,
2001; Lopez-Corona et al, 2003; Park et al, 2003; Lujan et al, 2004;
Benecchi et al, 2008; Lane et al, 2008; Rochester et al, 2009;
Schroder et al, 2009b). We attempted to evaluate our model in
cohorts with higher cancer rates by varying the event rate using
statistical imputation. We found that the model performed well
when the event rate was as high as 20%, but without recalibration
would not be clinically useful in cohorts with 30% or higher
detection rates. However, most repeat biopsy studies in screening
and clinical cohorts have found the cancer rate to be less than 30%
(Keetch et al, 1994; Roehrborn et al, 1996; Catalona et al, 1997;
Rietbergen et al, 1998; Djavan et al, 2000; O’Dowd et al, 2000;
Lopez-Corona et al, 2003; Park et al, 2003; Lujan et al, 2004; Lane
et al, 2008). The few studies that have found higher rates tended to
be older series (Fleshner et al, 1997; Letran et al, 1998; Durkan and
Greene, 1999); or involved saturation biopsies, usually after
previous sextant biopsies (Stewart et al, 2001; Walz et al, 2006);
or may have been enriched by higher risk patients due to features
such as atypia or HGPIN on previous biopsies or other factors
(Yanke et al, 2005; Benecchi et al, 2008).
The study is strengthened by the use of a well-characterised,
prospective cohort that was a part of a rigorously conducted clinical
trial. The use of decision analytical techniques and sensitivity analysis
demonstrate the utility in clinical decision making across different
threshold probabilities and cancer detection rates. An additional
advantage of using a panel of four kallikrein markers is that it does
not require additional procedures, such as urine collection or
prostatic massage, and can be performed by laboratories using an
aliquot from the same blood sample used to run the initial PSA. The
model can also be incorporated into laboratory reports, which can
then report the risk of prostate cancer for the patient along with the
measure of each kallikrein.
CONCLUSIONS
A statistical model based on a panel of four kallikreins has been
previously shown to predict the outcome of prostate biopsy in
previously unscreened men (Vickers et al, 2008, 2010c) and in men
who had a PSA test but no previous biopsy (Vickers et al,
2010a,b). In this study, we show that the model is highly predictive
of biopsy outcome. Use of the model to determine repeat biopsy in
men with elevated PSA would dramatically reduce rebiopsy rates,
while delaying the diagnosis of only a small number of cancers,
almost all of which are low grade.
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